Skip to content

RNA - Atrium Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchR

Atrium Therapeutics, Inc. Common Stock

RNA · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

R

RNAAtrium Therapeutics, Inc. Common Stock

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $16.77
52-wk low: $11.13
Prev close: $14.62
Mkt cap: $234.5M
Beta: 0.93
P/S: 6.5x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$42.1M

FC
Farallon Capital
Q1 2026 13F
$4.7M
position
TS
Two Sigma
Q2 2026 13F

Earnings

Reported May 14, 2026

Earnings came in 7.6% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -184.1%
Market cap: $235M

Valuation

P/S6.54
P/B1.02

Quality

Operating margin-753.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: RNA
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $234.52M
Beta: 0.93

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

1.0x

Profit margin

-184.1%

Op margin

-753.0%

ROE

-44.0%

$4.6M

position

MI

Millennium

Israel Englander · Q2 2026 13F

$2.7M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for RNA

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.97+7.6%

-$1.05 expected

Next report

What the street expects next

EPS expected

-$0.67

-$0.67 to -$0.67

Revenue expected

$11.3M

4 analysts

Estimate drift

+0.03

Change in 30 days

-44.0%

ROA-399.3%

Growth

Beta0.93